Cutaneous melanoma remains the most lethal of the primary cutaneous neoplasms, and
although the incidence of primary melanoma continues to rise, the mortality from metastatic …

The advent of immune checkpoint inhibition (ICI) using antibodies against PD1 and its
ligand PDL1 has prompted substantial efforts to develop complementary drugs. Although …

PURPOSE Preclinical data suggest the combination of an anti–programmed death receptor
1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with …

Purpose: Combinations of immune-checkpoint inhibitors (ICI) with other cancer therapies
have been approved for advanced cancers in multiple indications, and numerous trials are …

Background Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …

Hyperactivation of PI3K/AKT/mTOR and MAPK/MEK/ERK signaling pathways is commonly
observed in many cancers, including triple-negative breast cancer (TNBC) and melanoma …

Simple Summary To date, one of the reference therapies for the treatment of mutated BRAF
metastatic melanoma is based on the combination of BRAF and MEK inhibitors. Although …

PURPOSE The NCI-COG Pediatric MATCH trial assigns patients age 1-21 years with
relapsed or refractory solid tumors, lymphomas, and histiocytic disorders to phase II studies …

Individual participant data (IPD) from oncology clinical trials is invaluable for identifying
factors that influence trial success and failure, improving trial design and interpretation, and …

Increasing knowledge about the biology of melanoma and of immunology has led to the
development and regulatory approval of the immune checkpoint inhibitors ipilimumab …